Horse Health
Supports veterinary education in the field of equine lameness
EQUIOXX® (firocoxib) is now a corporate sponsor of the International Society of Equine Locomotor Pathology (ISELP) — a partnership that helps advance equine veterinarians’ knowledge of equine pain management.
“We are proud to support an organization that has done so much to enhance our understanding of equine lameness,” says Hoyt Cheramie, DVM, MS, manager, Equine Veterinary Services, Merial Limited. “We at Merial want to continue advancing the field by supporting ISELP.”
EQUIOXX is the first nontopical nonsteroidal anti-inflammatory drug (NSAID) approved in the past 17 years. With once-daily dosing, EQUIOXX provides 24 hours of relief from the pain and inflammation associated with equine osteoarthritis and is approved for use up to 14 days.1,2 As a corporate partner, EQUIOXX helps support ISELP’s ongoing continuing education programs for veterinarians. Each year, ISELP holds five seminars across the United States and in Europe. More than 200 veterinarians are members of the organization.
“ISELP was formed to provide knowledge on this continually evolving field,” says Rick Mitchell, DVM, Fairfield Equine Associates, P.C., and treasurer of ISELP. “As a practicing veterinarian, EQUIOXX is a product that I use every day. We know that the support of EQUIOXX and Merial will help us further advance the veterinary field as a whole.”
As the next generation of equine pain management, EQUIOXX is the first and only coxib NSAID approved for horses.2 In addition to being recommended by ISELP for equine osteoarthritis pain relief, EQUIOXX is approved for use up to 14 consecutive days by the United States Equestrian Federation (USEF) and American Quarter Horse Association (AQHA) when used at the recommended dose at least 12 hours prior to competing.3,4
“We are thrilled to support ISELP and its mission of advancing our understanding of equine pain management,” Dr. Cheramie says. “Even the most experienced equine veterinarians have much to learn about this issue and its effects.”
Merial is a world-leading, innovation-driven animal health company, providing a comprehensive range of products to enhance the health, well-being and performance of a wide range of animals. Merial employs approximately 5,700 people and operates in more than 150 countries worldwide. Its 2009 sales were over $2.6 billion. Merial is the Animal Health subsidiary of sanofi-aventis. For more information, please see www.merial.com.
Top of Page
|
